bepridil has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bepridil was identified predominantly in the octanol phase in the octanol/water partitioning studies." | 1.28 | Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist. ( Advani, SH; Chitnis, MP; Parekh, HK; Shallom, JM, 1991) |
| "Bepridil was found to be highly lipid soluble at physiological pH, and this property could be responsible for the modulation of the ADR activity observed in this study." | 1.28 | Bepridil enhances adriamycin-induced DNA biosynthesis inhibition in human myeloid leukemia cells. ( Advani, S; Chitnis, M; Parekh, H, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parekh, HK | 1 |
| Shallom, JM | 1 |
| Advani, SH | 1 |
| Chitnis, MP | 1 |
| Parekh, H | 1 |
| Advani, S | 1 |
| Chitnis, M | 1 |
2 other studies available for bepridil and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bepridil; DNA, Neoplasm; Drug Synergism; Humans; Leu | 1991 |
Bepridil enhances adriamycin-induced DNA biosynthesis inhibition in human myeloid leukemia cells.
Topics: Bepridil; DNA, Neoplasm; Doxorubicin; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-AB | 1990 |